Implications of multigene testing for hereditary breast cancer in primary care

被引:2
|
作者
Meghna S Trivedi [1 ]
Katherine D Crew [1 ,2 ,3 ]
机构
[1] Department of Medicine, College of Physicians and Surgeons, Columbia University
[2] Department of Epidemiology, Mailman School of Public Health, Columbia University
[3] Herbert Irving Comprehensive Cancer Center, Columbia University
关键词
Genetic testing; BRCA1; BRCA2; Hereditary breast cancer; Multigene testing;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
100214 ;
摘要
Approximately 1 in 8 women will develop breast cancer during their lifetime and the risk factors include age, family history, and reproductive factors. In women with a family history of breast cancer, there is a proportion in which a gene mutation can be the cause of the predisposition for breast cancer. A careful assessment of family and clinical history should be performed in these women in order to determine if a genetic counseling referral is indicated. In cases of hereditary breast cancer, genetic testing with a multigene panel can identify specific genetic mutations in over 100 genes. The most common genes mutated in hereditary breast cancer are the high-penetrance BRCA1 and BRCA2 genes. In addition, other mutations in high-penetrance genes in familial cancer syndromes and mutations in DNA repair genes can cause hereditary breast cancer. Mutations in low-penetrance genes and variants of uncertain significance may play a role in breast cancer development, but the magnitude and scope of risk in these cases remain unclear, thus the clinical utility of testing for these mutations is uncertain. In women with high-penetrance genetic mutations or lifetime risk of breast cancer > 20%, risk-reducing interventions, such as intensive screening, surgery, and chemoprevention, can decrease the incidence and mortality of breast cancer.
引用
收藏
页码:50 / 57
页数:8
相关论文
共 50 条
  • [21] Application of Multigene Panels Testing for Hereditary Cancer Syndromes
    Bilyalov, Airat
    Nikolaev, Sergey
    Shigapova, Leila
    Khatkov, Igor
    Danishevich, Anastasia
    Zhukova, Ludmila
    Smolin, Sergei
    Titova, Marina
    Lisica, Tatyana
    Bodunova, Natalia
    Shagimardanova, Elena
    Gusev, Oleg
    [J]. BIOLOGY-BASEL, 2022, 11 (10):
  • [22] Multigene Testing for Hereditary Cancer: When, Why, and How
    Offit, Kenneth
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (5.5): : 741 - 743
  • [23] Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer
    Ryu, Jin-Sun
    Lee, Hye-Young
    Cho, Eun Hae
    Yoon, Kyong-Ah
    Kim, Min-Kyeong
    Joo, Jungnam
    Lee, Eun-Sook
    Kang, Han-Sung
    Lee, Seeyoun
    Lee, Dong Ock
    Lim, Myong Cheol
    Kong, Sun-Young
    [J]. CANCER SCIENCE, 2020, 111 (10) : 3912 - 3925
  • [24] Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
    Shimelis, Hermela
    LaDuca, Holly
    Hu, Chunling
    Hart, Steven N.
    Na, Jie
    Thomas, Abigail
    Akinhanmi, Margaret
    Moore, Raymond M.
    Brauch, Hiltrud
    Cox, Angela
    Eccles, Diana M.
    Ewart-Toland, Amanda
    Fasching, Peter A.
    Fostira, Florentia
    Garber, Judy
    Godwin, Andrew K.
    Konstantopoulou, Irene
    Nevanlinna, Heli
    Sharma, Priyanka
    Yannoukakos, Drakoulis
    Yao, Song
    Feng, Bing-Jian
    Davis, Brigette Tippin
    Lilyquist, Jenna
    Pesaran, Tina
    Goldgar, David E.
    Polley, Eric C.
    Dolinsky, Jill S.
    Couch, Fergus J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (08) : 855 - 862
  • [25] Ethical implications of predictive DNA testing for hereditary breast cancer
    Di Pietro, ML
    Giuli, A
    Spagnolo, AG
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : I65 - I70
  • [26] Multigene hereditary cancer panel testing for patients with pancreatic cancer.
    McGill, Anna K.
    Solomon, Sheila R.
    Marshall, Megan L.
    Susswein, Lisa
    Fillman, Corrine
    Skora, Katherine A.
    Postula, Kristen J. Vogel
    Klein, Rachel
    Hruska, Kathleen S.
    Xu, Zhixiong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [27] Multigene Panel Testing in Turkish Hereditary Cancer Syndrome Patients
    Ates, Esra Arslan
    Turkyilmaz, Ayberk
    Alavanda, Ceren
    Yildirim, Ozlem
    Guney, Ahmet Ilter
    [J]. MEDENIYET MEDICAL JOURNAL, 2022, 37 (02): : 150 - 158
  • [28] Multigene assays: Implications for breast cancer staging
    Greene, Frederick L.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2017, 115 (06) : 663 - 664
  • [29] Who Should Have Multigene Germline Testing for Hereditary Cancer?
    Savage, Sharon A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4040 - +
  • [30] Impact of hereditary multigene panel testing for cancer survivors.
    Kapoor, Nimmi S.
    Swisher, Jennifer
    McFarland, Rachel E.
    Patrick, Mychael
    Curcio, Lisa D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (03)